ES2058426T3 - Empleo de antagonistas de serotonina en el tratamiento de apoplejia cerebral. - Google Patents

Empleo de antagonistas de serotonina en el tratamiento de apoplejia cerebral.

Info

Publication number
ES2058426T3
ES2058426T3 ES89116496T ES89116496T ES2058426T3 ES 2058426 T3 ES2058426 T3 ES 2058426T3 ES 89116496 T ES89116496 T ES 89116496T ES 89116496 T ES89116496 T ES 89116496T ES 2058426 T3 ES2058426 T3 ES 2058426T3
Authority
ES
Spain
Prior art keywords
apoplejia
brain
treatment
serotonin antagonists
serotonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89116496T
Other languages
English (en)
Inventor
Jorg Dr Traber
Gerhard-Wilhelm Dr Bielenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Troponwerke GmbH
Original Assignee
Troponwerke GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Troponwerke GmbH filed Critical Troponwerke GmbH
Application granted granted Critical
Publication of ES2058426T3 publication Critical patent/ES2058426T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Instructional Devices (AREA)
  • Hydrogenated Pyridines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cephalosporin Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

EL INVENTO SE REFIERE A MATERIA ACTIVA CON ACCION SEROTOMINA-ANTAGONISTICA Y CON LIGANTES EN RECEPTORES 5H-T1A. LA MATERIA ACTIVA SE UTILIZA COMO MEDICAMENTO PARA EL TRATAMIENTO DE LA APOPLEJIA CEREBRAL.
ES89116496T 1988-09-20 1989-09-07 Empleo de antagonistas de serotonina en el tratamiento de apoplejia cerebral. Expired - Lifetime ES2058426T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3831888A DE3831888A1 (de) 1988-09-20 1988-09-20 Arzneimittel zur behandlung von apoplexia cerebri

Publications (1)

Publication Number Publication Date
ES2058426T3 true ES2058426T3 (es) 1994-11-01

Family

ID=6363313

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89116496T Expired - Lifetime ES2058426T3 (es) 1988-09-20 1989-09-07 Empleo de antagonistas de serotonina en el tratamiento de apoplejia cerebral.

Country Status (15)

Country Link
US (3) US4988700A (es)
EP (1) EP0360077B1 (es)
JP (1) JP2669507B2 (es)
KR (2) KR0135307B1 (es)
AT (1) ATE91623T1 (es)
AU (1) AU619895B2 (es)
CA (1) CA1331139C (es)
DE (2) DE3831888A1 (es)
DK (1) DK175128B1 (es)
ES (1) ES2058426T3 (es)
FI (1) FI894404A (es)
HU (1) HU203475B (es)
IE (1) IE62697B1 (es)
IL (1) IL91660A (es)
PH (1) PH26920A (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2097607A1 (en) * 1990-12-24 1992-06-24 Marcel Hibert Use of certain glutarimide derivatives in the treatment of depression and mania
DE4135473A1 (de) * 1991-10-28 1993-04-29 Bayer Ag Triazaspirodecanon-methylchromane
DE4138756A1 (de) * 1991-11-26 1993-05-27 Troponwerke Gmbh & Co Kg Kombination mit neuroprotektiver wirkung
EP1063291A3 (en) * 1992-09-25 2001-04-25 Synaptic Pharmaceutical Corporation DNA encoding human alpha 1 adrenergic receptors and uses thereof
WO1994009765A1 (en) * 1992-10-23 1994-05-11 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
ATE255888T1 (de) 1998-06-01 2003-12-15 Ortho Mcneil Pharm Inc Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2000004012A1 (en) 1998-07-17 2000-01-27 Synaptic Pharmaceutical Corporation COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
DE19900544A1 (de) * 1999-01-11 2000-07-13 Basf Ag Verwendung von Verbindungen der Formel I zur Prophylaxe und Therapie der zerebralen Ischämie
US20040106623A1 (en) * 1999-07-16 2004-06-03 Synaptic Pharmaceutical Corporation Compounds specific for the human alpha1d adrenergic receptor and uses thereof
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US20040077996A1 (en) * 2002-10-22 2004-04-22 Jasperson Keith E. Drug infusion system with multiple medications
CN101247853B (zh) * 2005-04-13 2014-11-12 轴突公司 具有nos抑制活性的取代的吲哚化合物
AU2007240078B2 (en) * 2006-04-13 2013-07-25 Neuraxon, Inc. 1,5 and 3,6- substituted indole compounds having NOS inhibitory activity
MX2010005343A (es) * 2007-11-16 2010-08-09 Neuraxon Inc Compuestos indola 3, 5-sustituidos que tienen actividad inhibidora de la re-absorcion y el reciclo de nos y norepinefrina.
EP2219449A4 (en) * 2007-11-16 2010-10-27 Univ Arizona State METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING
EP2220075A4 (en) * 2007-11-16 2012-02-29 Neuraxon Inc INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN
KR102357405B1 (ko) 2021-05-07 2022-02-09 정진구 호흡기 운동기구

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8810748D0 (en) * 1988-05-06 1988-06-08 Beecham Wuelfing Gmbh & Co Kg Novel treatment

Also Published As

Publication number Publication date
FI894404A0 (fi) 1989-09-18
AU4145689A (en) 1990-03-29
IL91660A0 (es) 1990-04-29
DE58904960D1 (de) 1993-08-26
IE892990L (en) 1990-03-20
KR0146486B1 (ko) 1998-08-17
KR0135307B1 (ko) 1998-04-23
IE62697B1 (en) 1995-02-22
DK461689D0 (da) 1989-09-19
JPH02121935A (ja) 1990-05-09
AU619895B2 (en) 1992-02-06
CA1331139C (en) 1994-08-02
DE3831888A1 (de) 1990-03-29
DK175128B1 (da) 2004-06-07
FI894404A (fi) 1990-03-21
EP0360077A3 (de) 1992-03-11
HU203475B (en) 1991-08-28
US4988700A (en) 1991-01-29
US5155128A (en) 1992-10-13
PH26920A (en) 1992-12-03
ATE91623T1 (de) 1993-08-15
HUT52699A (en) 1990-08-28
JP2669507B2 (ja) 1997-10-29
KR900004352A (ko) 1990-04-12
IL91660A (en) 1993-08-18
US5070102A (en) 1991-12-03
EP0360077A2 (de) 1990-03-28
DK461689A (da) 1990-03-21
EP0360077B1 (de) 1993-07-21

Similar Documents

Publication Publication Date Title
ES2058426T3 (es) Empleo de antagonistas de serotonina en el tratamiento de apoplejia cerebral.
IT1218150B (it) Impiego in terapeutica degli antago nisti dei recettori serotoninergici 5ht3
DE3872109D1 (de) Vorrichtung zur transkutanen wirkstoffabgabe mit doppeltem durchgangsverstaerker.
ES2054988T3 (es) Quinuclidinas, su empleo como medicamentos y procedimiento para su produccion.
ES2052947T3 (es) Nueva forma unitaria, solida y porosa que comprende microparticulas y/o nanoparticulas asi como su preparacion.
IT7849523A0 (it) 3-1h-tetrazol-5-il-4h-pirido 1,2-a pirimidin-4-oni sostituiti utili in particolare come agenti terapeutici per inibire le reazioni allergiche e procedimento per la produzione dei detti derivati
MX9101913A (es) Derivados de quinazolinas para potenciar la actividad antitumoral
DK0412149T3 (da) Anvendelse af IL-7 til tilvejebringelse af lægemidler til stimulering af blodpladeproduktion
MX9206817A (es) Nuevos azoheterociclilmetil-cromanos, procedimiento para su obtencion y medicamento que los contiene.
BG99885A (en) Pyrene-pyridine derivatives
DE68910159D1 (de) Dosierform für Verabreichung in der Humanmedizin.
FI95653C (fi) Menetelmä lääkeaineen anto- ja/tai annostelumuodon valmistamiseksi
DK324687A (da) Transdermalt farmeceutisk praeparat
DE69013797D1 (de) Gehirnspezifische Zubereitung mit gesteuerter Abgabe.
LV10250A (lv) Jauni antiaritmijas lidzekli panemiens to iegusanai arstniecibas lidzeklis pielietojums
ATE80616T1 (de) Prostaglandin e1-derivate und ihre therapeutische anwendung.
IT8848251A0 (it) Composti correlati all'acetozolammi de con attivita' inibitrice dell'anidrasi carbonica, utili in particolare nel trattamento del glaucoma
ES2107414T3 (es) Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis.
ATE78482T1 (de) Substituierte hexahydroarylchinolizine.
IT1258315B (it) Derivati del flavone
IT8721591A0 (it) Protesi per il pene in particolareper incrementare il diametro del pene.
DK301489A (da) Cgrp til anvendelse til forbedring cerebral blodtilfoersel
ES2042864T3 (es) Empleo y agente para reducir los efectos secundarios de tnf.
IT8847797A0 (it) Derivati dell' 1.3 -diossalano e dell'1.3-diossano e loro impiegocome medicamenti
IT211441Z2 (it) Dispositivo di supporto, ad uso preferibilmente odontoiatrico, atto a mantenere il parallelismo dell'asse dell'utensile incisore, nei suoi spostamenti.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 360077

Country of ref document: ES